Schuetz Thomas J. 4
4 · Compass Therapeutics, Inc. · Filed Jan 10, 2024
Insider Transaction Report
Form 4
Schuetz Thomas J.
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Award
Common Stock
2024-01-09$1.93/sh+637,500$1,230,375→ 6,615,348 total - Award
Stock Option (Right to Buy)
2024-01-09+637,500→ 637,500 totalExercise: $1.93Exp: 2034-01-08→ CommonStock (637,500 underlying)
Footnotes (3)
- [F1]Represents restricted stock units ("RSU") granted to the reporting person on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on January 9, 2025.
- [F2]300,000 of the shares represents unvested restricted stock units ("RSU") granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. 500,000 of the shares represents unvested restricted stock units ("RSU") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 637,500 of the shares represents unvested restricted stock units ("RSU") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025.
- [F3]The options vest over 48 substantially equal monthly installments starting February 9, 2024.